NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

MSCA4Ukraine second call for applications: submission platform for host organisations opens in August

Published on | 4 months ago

Programmes MSCA   MSCA  

In April 2024 a €10 million top-up for the MSCA4Ukraine initiative was announced by the European Commission (Horizon Europe work programme 2023-2025 MSCA). For the second call it is expected approximately 50 fellowships (with a minimum duration of 6 months and a maximum duration of 24 months) will be awarded.

For the second call an Information for Applicants webpage with several call documents, including the application templates, a FAQ, and a webinar recording have been made available on the Scholars at Risk Europe website.

Applications must be submitted by prospective host organisations on behalf of displaced researcher(s) from Ukraine (candidate(s)). Host organisations can be academic or non-academic organisations in any EU Member State or Horizon Europe Associated Country. Organisations located in Ukraine are not eligible to apply as primary host organisations but can host researchers during a secondment arrangement.

Candidates: either postdoctoral researchers or researchers who, on or after 24 February 2022, were enrolled as doctoral candidates at a higher educational institution in Ukraine, and who have been displaced from Ukraine on or after 24 February 2022 are eligible to be nominated. Only one proposal per individual researcher can be submitted. Current and former MSCA4Ukraine fellows are not eligible to be nominated.

The submission portal will be opened on 5 August and closed on 5 September 23:59h CEST. The access link will be made available on the Information for Applicants webpage.

The evaluation and selection process will take place between October 2024 and February 2025 and the expected start of the fellowships between April and June 2025. Between May and November 2025 applicants from the reserve list will be offered funding should any awarded fellowship offers be declined, until all available funds have been disbursed.

All information related to the second (and previous) call for applications to MSCA4Ukraine is available on the Scholars at Risk Europe website.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1482 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.